Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition).
Jian Zhou,Hui-Chuan Sun,Zheng Wang,Wenming Cong,Jian-Hua Wang,Mengsu Zeng,Weiping Zhou,Ping Bie,Lianxin Liu,Tianfu Wen,Guohong Han,Maoqiang Wang,Ruibao Liu,Li Gong Lu,Zhengang Ren,Minshan Chen,Zhaochong Zeng,Ping Liang,Changhong Liang,Min Chen,Fuhua Yan,Wenping Wang,Yuan Ji,Jingping Yun,Dingfang Cai,Yongjun Chen,Wenwu Cheng,Shu-Qun Cheng,Chaoliu Dai,Wenzhi Guo,Baojin Hua,Xiaowu Huang,Wei-Dong Jia,Yaming Li,Yexiong Li,Jun Liang,Tianshu Liu,Guoyue Lv,Yilei Mao,Tao Peng,Wei Xin Ren,Hongcheng Shi,Guoming Shi,Kaishan Tao,Wentao Wang,Xiaoying Wang,Zhiming Wang,Bangde Xiang,Baocai Xing,Jian Ming Xu,Jiamei Yang,Jianyong Yang,Yefa Yang,Yunke Yang,Shenglong Ye,Zhengyu Yin,Bixiang Zhang,Boheng Zhang,Leida Zhang,Shuijun Zhang,Ti Zhang,Yongfu Zhao,Honggang Zheng,Jiye Zhu,Kangshun Zhu,Rong Liu,Yinghong Shi,Yongsheng Xiao,Zhi Dai,Gaojun Teng,Jianqiang Cai,Weilin Wang,Xiujun Cai,Qiang Li,Feng Shen,Shukui Qin,Jiahong Dong,Jia Fan +77 more
TLDR
The new guidelines were endorsed and promulgated by the Bureau of Medical Administration of the National Health Commission of the People’s Republic of China in December 2019 and reflect the real-world situation in China regarding diagnosing and treating liver cancer in recent years.Abstract:
Background: Primary liver cancer, around 90% are hepatocellular carcinoma in China, is the fourth most common malignancy and the second leading cause of tumor-related death, thereby posing a significant threat to the life and health of the Chinese people. Summary: Since the publication of Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2017 Edition) in 2018, additional high-quality evidence has emerged with relevance to the diagnosis, staging, and treatment of liver cancer in and outside China that requires the guidelines to be updated. The new edition (2019 Edition) was written by more than 70 experts in the field of liver cancer in China. They reflect the real-world situation in China regarding diagnosing and treating liver cancer in recent years. Key Messages: Most importantly, the new guidelines were endorsed and promulgated by the Bureau of Medical Administration of the National Health Commission of the People’s Republic of China in December 2019.read more
Citations
More filters
Journal ArticleDOI
Immunotherapies for hepatocellular carcinoma.
Josep M. Llovet,Josep M. Llovet,Josep M. Llovet,Florian Castet,Mathias Heikenwalder,Mala K. Maini,Vincenzo Mazzaferro,David J. Pinato,Eli Pikarsky,Andrew X. Zhu,Richard S. Finn +10 more
TL;DR: A review of the immune microenvironments underlying the response or resistance of hepatocellular carcinoma (HCC) to immunotherapies is presented in this paper, where current evidence from phase III trials on the efficacy, immune-related adverse events and aetiology-dependent mechanisms of response are described.
Journal ArticleDOI
Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma.
Yun-Fan Sun,Liang Wu,Liang Wu,Yu Zhong,Kai-Qian Zhou,Yong Hou,Zifei Wang,Ze-Fan Zhang,J. Xie,Chunqing Wang,Dandan Chen,Yaling Huang,Xiaochan Wei,Ying-Hong Shi,Zhikun Zhao,Yue-Hua Li,Zi-Wei Guo,Qichao Yu,Liqin Xu,Giacomo Volpe,Shuang-Jian Qiu,Jian Zhou,Carl Ward,Hui-Chuan Sun,Ye Yin,Xun Xu,Xiangdong Wang,Miguel A. Esteban,Huanming Yang,Jian Wang,Michael Dean,Yaguang Zhang,Shiping Liu,Xin-Rong Yang,Jia Fan +34 more
TL;DR: A comprehensive picture of the HCC ecosystem provides deeper insights into immune evasion mechanisms associated with tumor relapse, including those that dampen DC antigen presentation and recruit innate-like CD8+ T cells.
Journal ArticleDOI
Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors
Keiichi Kubota,Masatoshi Makuuchi,K Kusaka,Takashi Kobayashi,Kenji Miki,Kiyoshi Hasegawa,Yasushi Harihara,Tadatoshi Takayama +7 more
TL;DR: Vol-CT can accurately assess the extent of liver resection, individuals with normal liver function can undergo resection of up to 60% of the nontumorous parenchyma without the need for PE, and PE can be used to reduce the size of the resected tissue and increase the volume of the remnant liver to approximate the target limits in individuals with large tumors or minimally abnormal liver function.
Journal Article
Tumors of the Liver and Intrahepatic Bile Ducts
TL;DR: This new fascicle of the Atlas of Tumor Pathology is of the same high quality as most of the previous fascicles of the series, and combines, in a perfect balance, a profusion of excellent photographs and a well-written, sharp text.
Journal ArticleDOI
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial
TL;DR: In this article , the authors compared the overall survival of patients treated with FOLFOX-HAIC versus TACE as first-line treatment in large unresectable hepatocellular carcinoma.
References
More filters
Journal ArticleDOI
Global cancer statistics
TL;DR: A substantial proportion of the worldwide burden of cancer could be prevented through the application of existing cancer control knowledge and by implementing programs for tobacco control, vaccination, and early detection and treatment, as well as public health campaigns promoting physical activity and a healthier dietary intake.
Journal ArticleDOI
Global cancer statistics, 2012
Lindsey A. Torre,Freddie Bray,Rebecca L. Siegel,Jacques Ferlay,Joannie Lortet-Tieulent,Ahmedin Jemal +5 more
TL;DR: A substantial portion of cancer cases and deaths could be prevented by broadly applying effective prevention measures, such as tobacco control, vaccination, and the use of early detection tests.
Journal ArticleDOI
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more
TL;DR: In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo.
Journal ArticleDOI
EASL-EORTC clinical practice guidelines : management of hepatocellular carcinoma
Peter R. Galle,Alejandro Forner,Josep M. Llovet,Vincenzo Mazzaferro,Fabio Piscaglia,Jean-Luc Raoul,Peter Schirmacher,Valérie Vilgrain +7 more
TL;DR: The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.
Related Papers (5)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo,Richard S. Finn,Shukui Qin,Kwang Hyub Han,Kenji Ikeda,Fabio Piscaglia,Ari David Baron,Joong-Won Park,Guohong Han,Jacek Jassem,Jean-Frédéric Blanc,Arndt Vogel,Dmitry Komov,T.R. Jeffry Evans,Carlos Lopez,Corina E. Dutcus,Matthew Guo,Kenichi Saito,Silvija Kraljevic,Toshiyuki Tamai,Min Ren,Ann-Lii Cheng +21 more
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn,Shukui Qin,Masafumi Ikeda,Peter R. Galle,Michel Ducreux,Tae-You Kim,Masatoshi Kudo,Valeriy Breder,Philippe Merle,Ahmed O Kaseb,Daneng Li,Wendy Verret,Derek-Zhen Xu,Sairy Hernandez,Juan Liu,Chen Huang,Sohail M. Mulla,Yulei Wang,Ho Yeong Lim,Andrew X. Zhu,Ann-Lii Cheng,IMbrave Investigators +21 more